Results of Solanezumab clinical trials in people with Alzheimer’s disease announced
Published 24 August 2012
Eli Lilly and Company has announced that Solanezumab has not met key trial goals when tested as a potential treatment for Alzheimer’s disease in Phase 3 clinical trials.
The trials were in people with mild-to-moderate Alzheimer's disease.
Solanezumab is a monoclonal antibody that is being explored as a potential therapy for Alzheimer's disease. The two late-stage trials, known as EXPEDITION 1 and 2, tested solanezumab in people with mild-to-moderate Alzheimer's disease, compared with a placebo. Phase 3 clinical trials included more than 2,050 patients with mild-to-moderate Alzheimer's disease in 16 countries around the world. The trials were 18-months in duration.
Alzheimer's Society comment:'It is disappointing that Solanezumab didn't improve the symptoms of people with mild to moderate Alzheimer's disease. Promising therapies do sometimes fail at this stage, but this is particularly disheartening given that a similar treatment, Bapinezeumab, also recently fell at the last hurdle.'
'Currently there are 150 times more clinical trials focusing on treating people in the late stages of cancer than Alzheimer's disease. Further investment in trials is urgently needed to identify effective therapies to improve the lives of the 800,000 people in the UK currently living with dementia.'
Professor Clive Ballard
Director of Research
Alzheimer's Society
- Ends -
Notes to editors:
- One in three people over 65 will develop dementia
- Alzheimer's Society research shows that 800,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In less than ten years a million people will be living with dementia. This will soar to 1.7 million people by 2051
- Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them
- Alzheimer's Society works in England, Wales and Northern Ireland
- Alzheimer's Society supports people to live well with dementia today and funds research to find a cure for tomorrow. We rely on voluntary donations to continue our vital work. You can donate now by calling 0845 306 0898 or visiting alzheimers.org.uk
- Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk
